The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma
Maria Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, presents the outcomes from the Phase III CANOVA trial (NCT03539744) of venetoclax and dexamethasone (VenDex) compared to pomalidomide and dexamethasone (PomDex) for patients with t(11;14)-positive relapsed/refractory (R/R) multiple myeloma (MM) after at least two prior lines of therapy. VenDex increased numerically, but not significantly, the median progression-free survival (PFS) compared to PomDex. According to the EORTC QLQ-MY20, VenDex did not negatively impact patients’ quality of life. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
